Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.08

-2.9%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	4/17/2007 12:35:22 PM
	Read Replies (1) of 52153

Nice commentary on FDA's modified drug approval process by Scott Gottlieb. online.wsj.com Drug Danger By SCOTT GOTTLIEB April 17, 2007 Last week's recommendation by a FDA advisory panel against approving the Merck painkiller Arcoxia -- already in use in 63 countries around the world -- has dramatic implications for the future of drug research in this country. In effect, the agency is establishing new rules for approving drugs to treat some conditions for which other therapies exist, and you can bet drug companies are frantically re-examining their current R&D efforts. ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next